About Alexion Alexion, AstraZeneca’s Rare Disease group, was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines as well as supportive technologies and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion leads with the knowledge that patients and caregivers are people first, and by seeking to understand their experiences, Alexion is better able to serve their unique needs. Alexion’s pioneering legacy in rare diseases is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexi